Contract notice: Pharmaceutical products Tender, Germany - 27027014

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 05 Sep 2020

Other Information

Notice Type : Tender

TOT Ref.No.: 27027014

Document Ref. No. : 413551-2018

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : DAK-GESUNDHEIT
Office Name: DAK-Gesundheit
Address: Nagelsweg 27-31
Town: Hamburg
Postal Code: 20097


Phone: +49 402396-2682
Fax: +49 402396-3661
Germany
Email :vergabestelle@dak.de
URL :www.dak.de

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Lowest price
CPV code: 33600000, 33600000
CPV Description: Pharmaceutical products.

Conclusion of a non-exclusive discount agreement pursuant to - 130a (8) SGB V on the active ingredient nadroparin, ATC B01AB06, for the period 1.11.2018 31.10.2020

Reference Number: 1002305 - Nadroparin, ATC B01AB06

- 130a (8) SGB V allows the health insurance companies and pharmaceutical companies to issue framework discount contracts for the benefit of the statutory health insurance funds-To close medicines. In view of the pertinent statutory provisions on the awarding of public contracts, a regular process of active substance-based, public procurement procedures takes place in accordance with the regulations of the 4th part of the GWB by the DAK-G. For the medicinal product to be designated by the tenderer in Annex 2 to the contract with regard to the active substance nadroparin, ATC B01AB06, -DAK-G intends to conclude drug rebates with all interested pharmaceutical companies pending the entry into force of new drug rebates. A discount contract within the scope of the approval model for the o.g. Active ingredient will enter into force on 1.11.2018 and will end on 31.10.2020. Irrespective of this, it automatically ends with the entry into force of the exclusive contractit.

The DAK-Gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory accessibility of all pharmaceutical companies. Irrespective of this, it automatically ends with the entry into force of the exclusive contract for Nadroparin, ATC B01AB06, following a formal saleprocedure according to the regulations of the 4th part of the GWB with one or more contractual partners. In order to cope with the diversity of potential contractors under the authorization model, each pharmaceutical company will be able to conclude a framework contract at any time and under the same conditions during the contract period. The contract contract required for thisrations are available via the online portal www.dtvp.de/center under the subsection I.3. The following link is available for download.

Prerequisites for the conclusion or later accession to the contracts that enter into force on 1.11.2018 are the complete and timely transmission of the following documents / explanations / attachments (available for download under the I. 3. mentioned link)-to the following contact person at DAK-Gesundheit:

1) Letter of Request

2) Current Proof of Registration in the Professional or Commercial Register (see III.1.1.)

3) Self-declaration by the company (Annex A1) that none the exclusion criteria according to -- 123, 124 GWB are present (see III.1.1.). 4) self-declaration that for those medicines, for the interestst wish to conclude a contract under this procedure, that a drug license exists and that the bidder is entitled to distribution at the beginning of the contract (Appendix A2) (see III.1.1.)

5) Self-certification by the company that the statutory minimum wage requirements and adherence to the schedule (Annex A3) (see III.1.1.).

6) Recognition of contractual obligations-DAK-Gesundheit, in particular the prescribed discounts by signing the contract stamped with a company (twice original) by the interested party in the space provided.

7) The completed Annexes 1 and 2 to the contract (each 2-fold in the original). The interested party has here the medicines to the o.g. To enter active substance, which are the subject of the contract-

8) Effective pre-qualification notification of DAK health (see III.1.1 and III.1.2.)

The documents must be submitted by post to:

DAK Health

Henri Affinass (0032 50)

Nagelsweg 27- 31

20097 Hamburg

Furthermore, the attachment 2 as an Excel file at the same time to the mail address am_rabattvertraege@dak.de to send. Contracts under this model and o.g. Active ingredient eFirst completed with effect from 1.11.2018 and ending on 31.10.2020. Interested parties who wish to become partners at this time have the o.g., documents to be submitted by the 5th of the previous month at o.g. Submit job. It depends on the timely access to the DAK-health. Later accessions are possible at any time. In order during the term of the contract for 1, or 15th of the following month, the o.g. Documents, regardless of the desired accession, the DAK-health until the 5th of the previous month. Again, it depends on the timely access to DAK-health. Example: The bidder wished to join is due to be held on 15.7.20xx (following month), the documents would have to be submitted by 5.6.20xx (previous month)

Note: The publication is done here using the Open Procedure form. As already made clear, this is not one - the notice had to be used for technical reasons, as there is no form suitable for approval procedures.

1) Current proof of registration in the professional or commercial register (not als 6 months in case of dispatch) in accordance with the legislation of the country in which the company is established, eg current commercial register extract; Copy is sufficient.

2) Self-declaration of the company that none of the exclusion criteria according to -- 123, 124 GWB exists. Attachment A1 must be signed, provided with the company stamp and submitted in the original.

3) Eigenerklaerun(g) that, for those medicinal products for which the prospective buyer wishes to conclude a contract under this procedure, there is a marketing authorization and that the tenderer is entitled to sell at the inception of the contract (Appendix A2) (see III.1.1.) ) Self-declaration of the company, that observes and observes the legal requirements for the minimum wage and the tariff fidelity(Annex A3). Attachment A3 has to be signed, accompanied by a company stamp and submitted in original form.

DAK-Gesundheit has published a so-called pre-qualification procedure for pharmaceutical companies for the simplified participation in future drug discount tenders via the European Announcement Platform (EU Announcement 2015 / S 105- 190319-from 3.6.2015). If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before submission of the documents, he needs the company-specific proof of eligibility (proof of entry in the trade or professional register, self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB is present, safety certificatesupply of the statutory health insurance) with reference and addition of the Praequalifikationsbescheides in copy no longer to be attached. Attachment A2 must always be attached. Accordingly, the DAK health pre-qualification notification also serves as proof of DAK health open-house procedures, regardless of the value of the order.

Self-declaration that for those drugs, fin which the interested party wishes to conclude the contract in the context of this procedure, a drug license exists and that the bidder is entitled to the distribution at the beginning of the contract. Attachment A2 must be signed, provided with the company stamp and submitted in the original. DAK-Gesundheit has a so-called pre-qualification via the European announcement platformpublished for pharmaceutical companies for simplified participation in future drug rebate tenders (EU Notice 2015 / S 105-190319 of 3.6.2015). If the bidder has received an effective pre-qualification notice from DAK-Gesundheit in good time before submission of the documents, he needs the company-specific proof of eligibility (evidence dhe entry in the professional or commercial register, self-declaration of the company that none of the exclusion criteria acc. -- 123, 124 GWB is present, certificate of health insurance from the statutory health insurance) with reference and enclosing the Praequalifikationsbescheides in copy no longer to be enclosed. Attachment A2 must always be attached. The Praequalifikationsbescheid the DAK GesundhAccordingly, eit also serves as proof in open-house procedures of the DAK-Gesundheit.

The tender documents can also be sent by e-mail to the person responsible under I.1. be requested. The tender documents will then be sent by e-mail. Questions and information on the tender documents are available electronically (via bidder communication via the Vergabeportal www.dtvp.de) or in necessary individual cases by e-mail or in writing (by fax or letter) to those under I.1. to be addressed. They are to be formulated in German. Answers will be made available to all entrepreneurs who have requested the tender documents by means of a registration in anonymous form. The answers are den Entrepreneurs made available via bidding portal www.dtvp.de by means of bidder communication. Companies who have downloaded the tender documents without registration have to take responsibility for further communication and, if necessary, to the above mentioned. Contact point.

This publication is not a contract awardPublic Procurement Agreement as defined in the 2014/24 EU Joint Programming Council / Procurement Regulation. In order to ensure the widest possible degree of transparency for the envisaged contracts, it will be published in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form wThe contract notice will be used. The resulting conceptual requirements, such as the process name "Open Procedure", are solely due to the use of this announcement form and the publication platform, which is of additional importance, in particular subjection to public procurement regulations, unless it is mandatory for legal reasonsnd, is not related to this.

Announcement ID: CXP4YM5YJ2Z


Internet address (URL): www.dak.de

Documents

 Tender Notice